

Strategies to overcome low MHC-I expression in paediatric and adult tumours

J. Guillaume¹, A. Perzoli^{2,3} and M. Boes^{1,4,*}

¹Centre for Translational Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands

²Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands

³Department of Pediatric Oncology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands

⁴Department of Paediatric Immunology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands

*Correspondence: Centre for Translational Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

m.l.boes@umcutrecht.nl

Summary

Immunotherapy has made significant advancements in cancer treatments, improving patients' survival rates and quality of life. Several challenges still need to be addressed, which include the considerable fraction of incomplete curative responses in cancer patients, the development of therapy resistance by tumours, and the occurrence of adverse effects, such as inflammatory and autoimmune complications. Paediatric tumours usually exhibit lower responsiveness to immunotherapies compared to adult tumours. Although the underlying reasons are not yet fully understood, one known mechanism by which tumours avoid immune recognition is through reduced cell surface expression of major histocompatibility complex class I (MHC-I) complexes. Accordingly, the reduced presentation of neoantigens by MHC-I hinders the recognition and targeting of tumour cells by CD8+ T cells, impeding T-cell-mediated cytotoxic anti-tumour responses. MHC-I downregulation indeed often correlates with a poorer prognosis and diminished response to immunotherapy. Understanding the mechanisms underlying MHC-I downregulation in different types of paediatric and adult tumours is crucial for developing strategies to restore MHC-I expression and enhance anti-tumour immune responses. We here discuss progress in MHC-I-based immunotherapies against cancers.

Keywords: MHC-I expression, MHC-I downregulation, pediatric oncology, immunotherapy, immune evasion

Abbreviation: MHC-I: Major histocompatibility complex class I; NSCL: Non-small cell lung cancer; NB: Neuroblastoma; TMB: Tumour mutational burden; HLA-I: Human leukocyte antigen class I; NGS: Next-generation sequencing; ESC: Embryonic stem cell; pMHC-I: Peptide:MHC-I; TCR: T cell receptor; NK: Natural killer; KIR: Killer cell immunoglobulin-like receptor; IRF1: Interferon regulatory factor 1; miR: MicroRNA; GSL: Glycosphingolipid; LOH: Loss of heterozygosity; CTLA-4: Cytotoxic T-lymphocyte antigen; PD-1: Programmed cell death 1; TIL: Tumour-infiltrating T lymphocyte; IFN: Interferon; DUX4: Double homeobox 4; LNK: Lymphocytes adapter protein; N4BP1: Nedd4 Binding Protein; TNIP1: TNF-alpha-induced protein 3 interacting protein 1; DNMT: DNA methyltransferase inhibitor; HDAC: Histone deacetylase; RA: Retinoic acid.

Introduction

Each year, approximately 400 000 children and adolescents aged 0–19 years are diagnosed with cancer [1]. Immunotherapies, including immune checkpoint blockade, antibody-mediated therapy, and therapeutic cancer vaccines, demonstrated remarkable success in various adult cancers, including melanoma and non-small cell lung cancer (NSCL) [2, 3]. Compared with conventional treatments such as chemotherapy, radiotherapy, and surgery, immunotherapy has significantly improved survival rates and quality of life for patients [4, 5]. Not all patients, however, respond to immunotherapy or show partial reactivity, and some patients experience relapse after an initial response [6, 7]. Furthermore, paediatric tumours, such as neuroblastoma (NB), have shown limited responsiveness to immunotherapies [8]. The underlying reasons for this disparity are not yet fully understood.

A high tumour mutational burden (TMB), reflective of the number of DNA mutations in a tumour, has been denoted as a crucial predictor of response to immunotherapy [9, 10]. When leading to alterations in protein structure and composition, DNA mutations can result in the generation and possibly

presentation of alternative antigens known as neoantigens. Malignant cells can express neoantigens via major histocompatibility complex I (MHC-I) molecules. Consecutively, CD8+ T cells, through their T-cell receptors, recognize specific neoantigen peptide/MHC-I complexes, which trigger a cytotoxic immune response against cancer cells presenting specific neoantigen-derived peptides [11]. Interestingly, one major mechanism through which many tumours may avoid anti-tumour immunity is the downregulation of MHC-I, which causes reduced recognition by- and cytotoxicity of CD8+ T cells [12, 13]. Despite that MHC-I downregulation poses a huge challenge for current T-cell engaging immunotherapies, the understanding of the nature of dysregulation provides an opportunity to restore MHC-I expression in adult tumours. In contrast, our understanding of peptide/MHC-I complex formation and regulation and the neoantigen landscape in paediatric tumours remains incomplete. There are notable differences in cancer genetics, distribution and the micro-environment between adult and paediatric cancers [14]. Adult-type cancers usually develop by malignant conversion of end-differentiated cells. Paediatric cancers instead

Received: July 7, 2023; Accepted: December 6, 2023

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

more usually arise from undifferentiated embryonic tissues that inherently lack immunogenicity, including receptors and regulators involved in immunological responses [15]. Paediatric tumours are characterized by reduced expression of MHC-I, with a low TMB and a correspondingly low neoantigen load [9, 16]. Consequently, distinct therapeutic approaches must be developed when one aims to increase MHC-I expression on tumour cells, comparing cancers from adult-type with those of paediatric origins. Upregulating MHC-I expression in various cancer types holds promise as an immunotherapy strategy, that is to (re)activate immune control of tumours. It has the potential to improve response rates to immunotherapies and enhance efficacy against previously resistant cancers [17]. Therapeutic strategies that aim to restore MHC-I expression are currently being investigated in adult tumours, and involve the targeting of cell biological mechanisms that mediate MHC-I depletion [18, 19]. This review provides an overview of reduced MHC-I expression in relation to cancer development and its implications for immunotherapy efficacy, highlighting the differences between adult and paediatric tumours. Furthermore, we discuss potential therapeutic strategies to restore MHC-I expression and overcome immunotherapy resistance in paediatric tumours.

MHC-I expression and its role in anti-tumour immunity

Expression and function of MHC-I molecules in the body

The human leukocyte antigen class I (HLA-I) is the human equivalent of MHC-I and is highly polymorphic. HLA-I comprises three classical loci (HLA-A, -B, and -C) and three non-classical loci (HLA-E, -F, and -G) [11]. Its expression is highly regulated. For example, different tissues have extraordinary heterogeneity in classical HLA-I expression levels, as was shown using next-generation sequencing (NGS) and RNA sequencing data from human non-cancer tissues, which allowed for mapping HLA class I distribution throughout the body [20]. Classical HLA-I molecules are highly expressed in lymphatic tissues, lymph nodes, and spleen, mainly attributed to the increased presence of antigen-presenting cells, while the lowest classical HLA-I expression is found in privileged organs such as the brain, retina, testis, and muscle [21]. Furthermore, studies indicate that the expression of MHC-I varies during cell development [22, 23]. For instance, MHC-I expression in human embryonic stem cells (ESC) is initially low but can be swiftly induced upon cellular differentiation [24]. The structure of MHC-I molecules and the antigen presentation pathway have been expertly reviewed elsewhere [25, 26], and are summarised in Fig. 1.

The immune system can recognize malignantly transformed cells, such as through the expression of neoantigens loaded into MHC-I molecules that distinguish them from non-transformed cells. MHC-I molecules play a key role in the interaction between T cells of the adaptive immune system and malignant cells [27]. In brief, the T cell receptor (TCR) of CD8⁺ T cells can specifically recognise an antigen in the form of a short peptide that is bound by MHC-I molecules on the surface of target cells [28]. This triggers a plethora of different effector functions in CD8⁺ T cells, including the ability to eliminate cancer cells via cytokine/granzyme secretion, perforin, or FAS-dependent pathways [29, 30] (Fig. 1). In con-

trast, natural killer (NK) cells are inhibited by MHC-I via inhibitory receptors such as killer cell immunoglobulin-like receptors (KIRs) [31]. Therefore, tumours with low expression of MHC-I might be more susceptible to NK-cell-induced cytotoxicity, as proposed as the missing-self hypothesis by Kärre *et al.* [32]. The underlying mechanisms of MHC-I interaction with either CD8⁺ T cells and NK cells have been assessed in excellent reviews elsewhere [33–35].

MHC-I expression is crucial in the adaptive immune response, although it is not essential for cell viability or growth. As stated, tumours may employ MHC-I downregulation as a primary mechanism to evade recognition by the adaptive immune system [36], as is seen in a broad variation of tumour types including melanoma, breast, colorectal, and NSCL carcinomas [37–40]. While there has been extensive research on MHC-I expression in adult cancers, studies on paediatric cancers are relatively limited. This is accompanied with a low annual number of patients compared to adult cancers. It is important to recognize that paediatric tumours should be considered a distinct subset separate from adult tumours and they present unique therapeutic challenges mostly due to large differences in development, cancer genetics, distribution, and tumour microenvironment [14].

Differences between adult and paediatric tumours

Adult tumours typically arise from the accumulation of DNA mutations over time, with more malignancies occurring in individuals with advanced age [41]. Unhealthy lifestyle factors including smoking, alcohol consumption, and UV exposure are known triggers for such mutations and subsequently tumorigenesis [42, 43]. However, the same paradigm cannot be applied to paediatric tumours, which more often originate from undifferentiated stem or progenitor cells that undergo oncogenic mutations during specific developmental stages [44–46]. It is likely that these cells possess a distinct transcriptional program, influenced by genetic or epigenetic alterations, that promotes tumour development. Paediatric tumours often do not harbour MHC-I expression in the first place, as evidenced by various studies (see Tables 1 and 2). Since most paediatric tumours harbour a significantly lower presence of mutations compared to adult tumours, paediatric tumours often lack identifiable targets to develop specific and effective therapies.

MHC-I expression and downregulation during tumour development

The infiltration of specific antitumour CD8⁺ T cells into the tumour tissue in the course of normal immune defence results in their recognition and elimination of MHC-I positive cells, which in a tug-of-war type of response can induce in tumour cells an overall selection process that benefits MHC-I negative cells [75]. Eventually, tumours can become completely MHC-I negative and acquire an encapsulated structure that is ‘non-permissive’ for immune attack [58]. This phenotype is often associated with metastasis, although the MHC-I expression phenotype in metastatic tumours can exhibit considerable diversity and may not always involve a total loss of MHC-I expression [76] (Figure 2).

Genetic defects that affect MHC-I presentation in tumours include point mutations, base pair insertion, or deletion, which are irreversible processes. Examples include genetic mutations and deletions in the MHC-I heavy chain or $\beta 2M$ genes, or




Figure 1. Antigen processing and presenting pathway. Proteins are degraded into peptides by the proteasome and transported from the cytosol into the ER lumen by TAP transporter. In the ER, MHC-I molecules are folded, which allows them to bind to specific peptides, called antigens. The resulting peptide:MHC-I (pMHC-I) complex is transported to the plasma membrane through the Golgi apparatus. Then, CD8+ T cells recognize and bind the pMHC-I complex via their TCR receptor and their co-receptor CD8. The TCR complex is formed; it consists in the TCR α - β subunits and three CD3 co-receptor signalling subunits (γ , ϵ , δ). CD8 recruits Lck, that phosphorylates ITAM motifs on the intracellular part of CD3. Next, Zap70 binds to the complex and causes the activation of various downstream pathways leading to the activation of the cell. CD8+ T cells induce apoptosis in the tumour cells, secrete perforin, and granzymes, and upregulate the expression of Fas ligand on the cell surface (created with Biorender.com).

Table 1. Examples of adult tumours with changed MHC-I expression relative to healthy cells

Tumour type	MHC-I expression	Prognostic indication	References
Melanoma	Downregulated	Association with immunotherapy resistance and T cells infiltration	Lim <i>et al.</i> [38] Lee <i>et al.</i> [47] Shklovskaya <i>et al.</i> [48]
NSCL	Loss or downregulated	Association with poor survival and ICIs outcome	Montesion <i>et al.</i> [39] Hurkmans <i>et al.</i> [49] Ichinokawa <i>et al.</i> [50]
Colorectal cancer	Loss or downregulated	Worst CD8+ T cells activation and response	Zhang <i>et al.</i> [51] Geng <i>et al.</i> [52] Moretti <i>et al.</i> [53]
Breast cancer	Loss or downregulated	Poor prognosis and response	Fang <i>et al.</i> [54] Dusenbery <i>et al.</i> [37] Zhao <i>et al.</i> [55]
Prostate cancer	Downregulated		Kowarschik <i>et al.</i> [56] Korentzelos <i>et al.</i> [57] Garrido <i>et al.</i> [58]

Table 2. Examples of paediatric tumours with changed MHC-I expression relative to healthy cells

Tumour type	MHC-I expression	Prognostic indication	References
Neuroblastoma	Low or absent	Limitation of cytotoxic T-cell engagement, functional alteration of the TME	Cornel <i>et al.</i> [59] Lorenzi <i>et al.</i> [60] Pistoia <i>et al.</i> [61] Wölfel <i>et al.</i> [62]
Medulloblastoma	Low or absent	Poor prognosis	Garancher <i>et al.</i> [63] Smith <i>et al.</i> [64] Smith <i>et al.</i> [65]
Ewing sarcoma	Low	Poor prognosis	Biele <i>et al.</i> [66] Peters <i>et al.</i> [67] Thiel <i>et al.</i> [68]
ALL and AML	Expressed or downregulated	Downregulation of MHC-I is infrequent but functionally relevant	Chen <i>et al.</i> [69] Depreter <i>et al.</i> [70] Kang <i>et al.</i> [71]
Osteosarcoma	Downregulated, variable expression	Association with immuno-suppressive TME	Liu <i>et al.</i> [72] Tian <i>et al.</i> [73] Delgado <i>et al.</i> [74]




Figure 2. MHC-I expression and downregulation during tumour development. Tumour cells are normally MHC-I positive at early stage of the tumour development. Mutations, caused by environmental or genetic factors, are translated in neoantigens, which can be presented on the cell surface via MHC-I. CD8+ T cells recognize pMHC-I and trigger a cytotoxic immune response against tumour cells that present the neoantigens. The immunity selection causes heterogeneity in MHC-I expression amongst tumour cells. Finally, tumours can be completely MHC-I negative and the CD8+ T cells response is repressed. MHC-I negative tumours lead to the formation of metastasis (created with BioRender.com).

in the TAP or Tapasin genes, that lead to downregulation or complete loss of MHC-I [77]. Indeed, a study showed that restoring the expression of TAP-1/TAP-2 in murine melanoma knockout models enhances cell-surface expression of MHC-I and significantly reduces subcutaneous tumour growth [78]. In addition, mutations in the $\beta 2M$ gene correlate with the absence of MHC-I in metastatic melanoma patients [79]. Tumour cells can also contain reversible defects that affect MHC-I expression. MHC-I downregulation in cancer can also be attributed to epigenetic and/or (post)-transcriptional dysregulation of pathways involved in the transcription of MHC-I heavy chain, $\beta 2M$ genes, or components of the antigen processing and presentation machinery. Transcription factors such as interferon regulatory factor 1 (IRF1), NF- κ B, and NLRC5 play crucial roles in regulating MHC-I gene expression. Reduced expression of NF- κ B and IRF1 in certain aggressive NB cell lines correlates with significantly decreased expression of MHC-I [60]. Furthermore, truncating/splice mutations or missense mutations in NLRC5 are associated with poor prognosis, low MHC-I expression, and diminished levels of infiltrating immune cells in melanoma [80]. In addition, loss of MHC-I in cancer can result from post-transcriptional regulation of mRNA, mediated by non-coding RNAs. MicroRNAs (miRs) are key players in this process, impacting various components of the antigen processing and presentation machinery. For instance, the overexpression of two specific miRs in melanoma cells is found to downregulate the TAP1 protein, thereby reducing the expression of MHC-I cell-surface antigens [81]. Moreover, alterations in several oncogenic pathways, including MAPK, epidermal growth factor receptor, HER2, and c-MYC pathways, can also influence MHC-I expression in various cancers [12].

In cancer cells, MHC-I expression can be modulated by the perturbation of trafficking and degradation of MHC-I molecules. At the plasma membrane, MHC-I molecules can diffuse laterally, which provides the option to interact with other cell-surface molecules [82]. For example, MHC-I molecules were shown to interact with glycosphingolipids (GSLs), hydrophobic ceramide units decorated with variable hydrophilic sugar structures [83]. Overexpression of GSLs has been observed in several tumour types including glioma, AML, and adenocarcinomas [84–86]. High levels of GSLs interfere with the accessibility of T cells and immune cell receptors to bind tumour-expressed molecules including MHC-I [83]. Another way through which tumour cells regulate MHC-I display and its accessibility on the cell surface is via MARCH proteins. MARCH9 and its homologue MARCH4 target and degrade MHC-I molecules in a ubiquitin-dependent manner [87]. Several tumours overexpress MARCH proteins which may support immune evasion by lowering the cell-surface display of MHC-I proteins [88]. Furthermore, MARCH9 is required at the trans-Golgi network to promote MHC-I endosomal recycling. The acid environment of the endosome promotes the release of the bound peptide allowing for new peptide loading to occur into MHC-I, after which the MHC-I molecule can be recycled to the cell surface [87]. However, tumour cells may eliminate this recycling option by decreasing the endosomal below pH 4.5 leading to full and definite dissociation and degradation of the MHC-I complex [89].

Correlation between MHC-I expression and TMB

The advent of high-throughput methods, most notably NGS, revolutionized the detection and quantification of acquired

mutations at the individual cancer genome level. TMB serves as a quantifiable measure of the number of mutations present in a tumour. Theoretically, the higher the TMB, the greater the number of neoantigen peptide possibilities that are available for presentation via MHC-I molecules to CD8+ T cells [9]. At the time of writing this review, the correlation between the number of mutations and MHC-I phenotype is an active area of research.

Certain adult cancers, such as melanoma, exhibit a high TMB [90, 91]. The analysis of 9175 tumour samples showed that tumours with a low TMB often exhibit low MHC-I expression, and vice versa [92]. In contrast, paediatric tumours generally exhibit a low TMB. A comprehensive analysis encompassing 961 tumours from children, adolescents, and young adults showed that mutation frequencies in paediatric tumours were approximately 14 times lower than in adult cancers [93, 94]. The insufficient neoantigen density in malignancies with low TMB, such as AML and paediatric brain cancers, requires more powerful strategies for the accurate identification of immunogenic neopeptides that can be presented via MHC-I to CD8+ T cells.

Furthermore, changes in neoantigen presentation can occur independently from MHC-I expression. In cancer, events such as alternative mRNA splicing, premature termination of translation, and protein misfolding often occur and all these are involved in antigen presentation [95]. For example, in leukemic cells, a naturally occurring antigen encoded by alternatively spliced TTK transcript has been identified. The isolated T cells specific for this antigen fail to recognize most leukemic cells expressing the alternative TTK transcript [96]. The so-called loss of heterozygosity (LOH), which is a loss of either the maternal or paternal HLA haplotype, reduces the capacity of MHC-I to present antigen. Indeed, it has been shown that patients with tumours that underwent LOH were less responsive to immunotherapy compared to patients with tumours that had intact alleles [97]. Furthermore, LOH in NSCLCs was associated with higher TMB and increased immune evasion [98]. Overall, these data suggest that not all neoantigens are necessarily immunogenic targets for antigen-specific CD8+ T cells, highlighting a potential role for NK-cell-based immunotherapies. Furthermore, the numerous differences observed between paediatric and adult tumours underscore the importance of considering paediatric cancer as a distinct entity when developing therapeutic strategies.

Implication in immunotherapy

The discovery of immune checkpoints, such as cytotoxic T-lymphocyte antigen (CTLA-4) and programmed cell death 1 (PD-1) has been crucial to the development of cancer immunotherapy. Despite the improved therapeutic prospects, treatment with immune checkpoint inhibitors (ICIs) still has considerable limitations and challenges. Although a significant fraction of patients respond to ICIs, a large percentage of patients experience intrinsic or acquired resistance, partially depending on the tumour type. Intrinsic resistance refers to patients who do not respond at all to ICIs, while acquired resistance alludes to patients who have a period of an initial response to ICI therapy followed by progression of the disease [99]. Acquired resistance to ICIs in many types of cancer is associated with alterations in the MHC-I-related pathways [38, 47]. The efficacy of these immunotherapies is mainly based on the (re)activation of CD8+ T cells. If MHC-I is not present or is downregulated, CD8+ T cells cannot get

(re)activated and this usually correlates with a poor response to immunotherapy.

MHC-I downregulation and immunotherapy response

MHC-I expression level can be associated with the efficacy and duration of immunotherapy treatments. In a study for the expression of MHC-I in 10 metastatic lesions obtained from a melanoma patient undergoing immunotherapy, eight metastases were regressing after immunotherapy while two were progressing. The eight regressing metastases showed high levels of MHC-I expression, whereas the two progressing lesions had low MHC-I levels [100]. Similar results were found in two other studies performed by the same group. Briefly, a quantitative score was developed to correlate the tumour cell expression of antigen-presenting MHC-I molecules with the response to PD-1 monotherapy. They found robust MHC-I expression in all patients who responded to the therapy [48]. Furthermore, they described MHC-I downregulation as a hallmark of resistance to PD-1 inhibitors in melanoma patients [47]. Overall, MHC-I expression seems to play a major role in the response to immunotherapy. Understanding how MHC-I is downregulated might be crucial to determine the mechanism underlying the acquired resistance to immunotherapies. Restoring MHC-I expression could be a promising solution to solve the problem of adaptive resistance.

How MHC-I downregulation can contribute to adaptive immunotherapy resistance

Tumours with a high TMB usually respond better to anti-CTLA-4 and anti-PD-1 therapies [91, 101–103]. Interestingly, mutations in the $\beta 2M$ gene or genes involved in the IFN- γ pathway are positively associated with resistance to PD-1 treatment [104]. Those mutations can be responsible for MHC-I expression downregulation. Moreover, several studies showed a direct correlation between MHC-I expression and the increased presence of tumour-infiltrating T lymphocytes (TILs) [47, 48, 51]. For instance, a high intratumoural infiltration of CD8+ TILs can be positively associated with high MHC-I levels and with the regression of melanoma lesions. In contrast, the absence of TILs is often accompanied with low MHC-I expression and progression of tumour lesions [105]. Furthermore, LOH of the HLA locus did lead to a higher resistance against TILs in a CRC tumour [97] while another study showed that LOH of the HLA locus is associated with increased PD-L1 expression [98]. TIL profiling is also another valuable method to predict immunotherapy outcomes. In a study where samples from 46 patients with metastatic melanoma were obtained before and during anti-PD-1 therapy, patients responding to the treatment showed proliferation of intratumoural CD8+ T cells, which directly correlated with a reduction in tumour size [106]. Interestingly, not only TIL presence but also TIL differentiation and localization have been shown to determine clinical outcomes [107]. As CD8+ TILs recruitment and activation depend on MHC-I expression, restoring MHC-I expression might increase the presence, proliferation, and activity of TILs inside the tumour, and lead to a higher response to immunotherapy.

MHC-I expression in paediatric tumours

Fewer children than adults with cancer benefit from treatment with ICIs. While many factors may be responsible, this difference likely is contributed by the low TMB as well as low MHC-I expression in the majority of paediatric tumours

[108]. Preclinical data suggested CTLA-4 as a promising target in paediatric melanoma and other solid tumours because of its high expression by TILs [109]. However, a recent phase I study (NCT01445379) with paediatric cancer patients treated with CTLA-4 blockade (Ipilimumab) revealed many side effects after patients were administered a single dose and did not show an anti-tumoural response [110]. Similar results were obtained in a phase II study of PD-1 antibody in children affected by bone sarcomas. They found similar side effects to the adult studies, but no antitumour effects (NCT02301039) [111]. Furthermore, in the clinical trial KEYNOTE-051 (NCT02332668), a paediatric study including patients affected by melanoma, lymphoma, solid tumour, and classical Hodgkin lymphoma, demonstrated tolerance to PD-1 therapy at adult doses, and again no responses towards tumour regression [112]. Overall, checkpoint inhibition-based immunotherapy has so far not proven overly successful in paediatric clinical trials [113].

Rescue MHC-I low phenotype

The reduction of MHC-I on selected tumour cell types eliminates the inhibitory signals initiated by MHC-I, leading to enhanced NK cell activation and increased cytotoxicity [26, 114, 115]. In response, tumours have developed various mechanisms to evade NK cell-mediated cytotoxicity. For instance, tumours often secrete or express factors such as TGF- β , NKG2D-L, IDO, or PGE2 [116, 117], which impair NK-cell function and hinder their infiltration into the tumour site [118]. In addition, tumours may transiently upregulate MHC-I expression in response to NK cells, enabling them to evade recognition by these cells [119–121]. Next to NK cells, $\gamma\delta$ T cells can also target tumour cells in an MHC-I-independent manner. Indeed, De Vries *et al.* have demonstrated that $\gamma\delta$ T cells are abundantly present in mismatch repair-deficient (MMR-d) cancers with genomic inactivation of $\beta 2M$. Such $\gamma\delta$ T cells, mainly comprising V δ 1 and V δ 3 subsets, harbour an antitumoural response to MHC-I-negative, but not MHC-I-positive MMR-d tumours. Furthermore, MMR-d tumours from patients that received ICI treatment with both anti-PD1 and anti-CTLA-4 contained more $\gamma\delta$ T cells than before the initiation of the treatment [122]. If tumours can increase MHC-I expression in response to the presence of $\gamma\delta$ T cells remains to be proven. Tumours thus exhibit adaptability in evading both NK and T-cell-mediated cytotoxicity, facilitating immune escape.

To rescue MHC-I expression, the type of lesion will dictate the type of effective approach. ‘Hard’ lesions are caused by structural genetic alterations (for example mutations in $\beta 2M$ or other MHC-I-related genes) and are irreversible. Gene editing appears to be the only method to reverse the mutated genes. ‘Soft’ lesions are caused by epigenetic and/or (post)-transcriptional dysregulation, for example, destabilization of NF- κ B, IRFs, and NLCR5 transcription factors, and are usually reversible defects [75, 123]. The intrinsic reversible nature of these dysregulations provides an opportunity to restore MHC-I expression.

Therapeutic strategies to rescue MHC-I ‘soft’ lesions

Post-transcriptional regulation of MHC-I

Loss of MHC-I expression due to (post)-transcriptional regulatory changes in genes such as MHC-I heavy chain, $\beta 2M$,

or other components of the APM, can be potentially restored [123]. Different pathways can regulate the transcription of MHC-I genes as well as other genes responsible for the APM. One potential target to upregulate MHC-I expression is the interferons (IFNs) signalling pathway. Both type I and type II IFN pathways, when activated, can induce dimerization of STAT proteins, which then migrate to the nucleus and regulate the transcription of numerous genes, including MHC-I genes [124]. MHC-I could be induced, with a more than 50% increase after exposure to IFN- γ in 14/19 human tumour cell lines [125]. Loss of MHC-I can also be attained by dysregulation of the IFN- γ pathway: defects in the IFN- γ signalling pathway melanoma cell lines were caused by the absence of STAT-1 phosphorylation. IFN- α treatment could induce STAT-1 phosphorylation and consequently MHC-I expression [126]. Such data carries relevance as IFN- γ treatment is being applied in clinical practice [127]. Adenovirus vectors with IFN- γ cDNA have been tested in clinical trials to treat cutaneous lymphoma and melanoma [NCT00394693, [128]]. Various clinical trials have been using IFN- γ as an adjuvant for vaccine therapies and chemotherapies [NCT00428272, NCT0049-9772, NCT00824733, NCT00004016]. Alternatively, inhibition of negative regulators of IFN- γ signalling could reactivate the pathway and increase MHC-I expression. Several proteins, such as double homeobox 4 (DUX4), lymphocytes adapter protein (LNK), or protein tyrosine phosphatases, have been implicated in impaired IFN signalling in cancer [129–131]. Therefore, inhibiting these proteins might be beneficial when combined with immunotherapy to increase MHC-I expression and enhance T-cell-mediated cytotoxicity. However, as many of these proteins have not been correlated directly with MHC-I expression yet, further investigation is needed.

Another potential target for MHC-I upregulation is the NF- κ B pathway. The NF- κ B pathway consists of many inducible transcription factors (Rel, p65, RelB, p105/p50, p100/p52), which under normal conditions are inhibited by I κ Bs and IKKs. After cell stimulation, NF- κ B is activated and enters the nucleus to bind and transcribe target genes, including MHC-I. The NF- κ B signalling pathway is a key regulator of cellular immunity, inflammation, and stress, and is furthermore involved in cell differentiation, proliferation, and apoptosis [132]. The NF- κ B pathway is often altered in both solid and haematopoietic malignancies [133]. Lorenzi *et al.* showed that transfecting NB cell lines with both NF- κ B p65 and IRF1 transcription factors induces optimal recovery of cell-surface MHC-I expression. They observed a critical dependence of MHC-I/APM reactivation on the NF- κ B/IRF1 pathway [60]. Alternatively, as for the IFN pathway, negative regulators of the NF- κ B pathway could be targeted. Previous research in our lab identified two major negative regulators of MHC-I via NF- κ B signalling in NB; Nedd4 Binding Protein 1 (N4BP1) and TNF- α -induced protein 3 interacting protein 1 (TNIP1). Targeting NA4BP1 or TNP1 could result in strong activation of NF- κ B signalling, which should substantially increase MHC-I expression [134].

Finally, a third regulator of MHC-I transcription is NLRC5 (NOD-like receptor family, caspase recruitment domain containing five). Several studies with NLRC5-deficient mice showed that NLRC5 is a key factor in the transcriptional regulation of MHC-I [135, 136]. Various expressional and functional defects of NLRC5 have been found in many cancers, associated with impaired cytotoxic T-cell activation and

poor patient prognosis [137, 138]. No specific compounds targeting NLRC5 have been reported yet. However, the expression of NLRC5 is highly induced following the activation of STAT1 in response to IFN- γ stimulation [55]. Targeting pathways that regulate the transcription of MHC-I or β 2M genes or other components of APP pathway, is a promising strategy to restore MHC-I expression and enhance the response to immunotherapies in cancer patients.

Alternative strategies to upregulate MHC-I ‘soft’ downregulation

For cancers that have lost MHC-I expression due to epigenetic silencing mechanisms, it should be possible to restore MHC-I expression by reversing the repressive epigenetic status of the MHC-I-related genes. In support, recent work showed one such example, in human breast cancer types in which MHC-I genes were found to be methylated in some cases, suppressing the expression of those genes. Treatment with a DNA methyltransferase inhibitor (DNMT) in a murine breast cancer model upregulated MHC-I expression in tumour cells, which promoted the recruitment of CD8+ T cells to the micro-environment [139]. The prolonged treatment with a high dose of the DNA hypomethylating agent 5-AZA-2'-deoxycytidine showed the induction of de novo expression of MHC-I genes in MHC-I-negative melanoma cell lines [140]. Histone deacetylase (HDAC) inhibitors can also regulate MHC-I gene expression, inducing hyperacetylation of histones, thereby activating transcription. Combination therapy of HDAC inhibitors and ICIs is currently tested in melanoma patients and in patients with other cancer types [59, 141, 142].

Various oncogenic pathways have been reported to affect the expression of MHC-I, β 2M, and other APM components in cancer, including the MAPK/ERK pathway. The MAPK/ERK pathway regulates NF- κ B transcription factors and has been suggested to negatively influence MHC-I expression by decreasing IRF1 activity and STAT1 expression [143, 144]. Therefore, inhibiting the activity of this pathway might restore MHC-I expression. Indeed, it was shown that mutational activation of MAPK/ERK pathway inhibits MHC-I expression in NSCLC and contributes to the poor response to immunotherapy. Accordingly, the treatment of an NSCLC cell line with trametinib, a MEK inhibitor, increased MHC-I expression [145]. Therefore, inhibiting these oncogenic pathways that regulate MHC-I transcription might constitute another promising strategy to restore MHC-I expression.

Potential therapeutic strategies to rescue MHC-I ‘hard’ lesions

The MHC-I heavy chain and β 2m light chain are essential for antigen presentation. ‘Hard’ lesions in MHC-I genes require gene replacement or gene editing to rescue and recover MHC-I expression. *In vitro*, this has been accomplished by the transfection of MHC-I pathway genes into cancer cell lines [146]. Similarly, gene therapy with a β 2M-adenoviral vector has been proven successful in restoring MHC-I expression in human melanoma cell lines with β 2M mutations [147]. A major challenge is the transduction of cancer cells in both the primary site and the metastases. If not all tumour cells in all locations are successfully transduced, MHC-I negative clones will proliferate and metastasize. Furthermore, gene therapy must affect cancer cells only and not damage healthy tissue. Obtaining this result is undeniably challenging with the current therapies.

Of note, in contrast to hard lesions in MHC-I heavy and light chain, genetic mutations in other components of the MHC-I antigen presentation, including the PLC members tapasin, ERp57, TAP, and calreticulin, still allow for MHC-I presentation albeit a different peptide repertoire [148]. For example, defective TAP transport leads to the presentation of an altered peptide repertoire, which contains more TAP-independent peptides. Some of these peptides may be selectively presented by TAP-deficient tumour cells and are often considered neoantigens that can potentially be recognized by the immune system [149].

Rescue MHC-I low phenotype in paediatric tumours through induced differentiation

Clinical research on mechanisms that induce MHC-I expression in paediatric tumours is still ongoing. Whether MHC-I genes are mutated or not in paediatric tumours is still largely unknown. However, considering their origin and low mutational load, MHC-I gene sequences are most probably unaltered. Therefore, there is a possibility that MHC-I expression can be induced *de novo* in paediatric tumours. The consensus is that paediatric tumours arise from precursor cells or ESCs. Already in the 1970s, Artzt and Jacob noted that MHC-I molecules, and β 2M, are absent in undifferentiated ESCs [150]. Studies in the 1980s showed that MHC-I expression in ESCs can be induced by retinoid treatment [151, 152]. Retinoids, derivatives of vitamin A, are currently being used to treat several types of cancer, including NB and leukaemia, and are known to induce differentiation, apoptosis, and inhibition of proliferation of tumour cells [153, 154]. Retinoic acids (RA) and cholesterol induce differentiation of NB cells [155], and in NB, RA can induce NF- κ B transcription factor activity [156]. All this suggests that RA induces differentiation through the stimulation of NF- κ B, which has an important role in the induction of MHC-I transcriptional activation. In this way, MHC-I expression could be induced *de novo* and could enhance the outcome of immunotherapies in paediatric tumours. In paediatric tumours, where MHC-I genes are most likely not mutated or dysregulated, differentiation therapy might be a solution. Further investigations are needed to understand the mechanism in place and consequently find potential therapeutic strategies.

Conclusion

The MHC-I antigen processing and presentation pathway plays a critical role in inducing CD8⁺ T-cell responses and is essential for an effective cytotoxic T-cell response. Unfortunately, tumours often exhibit downregulation of MHC-I, which is associated with poorer treatment responses and the development of therapy resistance in various cancer types. The loss of MHC-I expression can stem from defects in the antigen presentation pathway, epigenetic silencing of gene regulatory elements, loss of transcription factors, or defects in regulatory signalling pathways. Fortunately, therapeutic restoration of MHC-I expression holds promise for improving the outcomes of immunotherapies, depending on the specific mechanism of downregulation. We here highlighted several beneficial approaches to rescue MHC-I downregulation and enhance the response to immunotherapy in adult tumours. One strategy involves targeting MHC-I transcription regulators, such as IRF, NF- κ B, or NLRC5, which show potential as valuable and promising therapeutic targets. Another approach

involves reversing MHC-I expression by targeting repressive epigenetic markers or oncogenic pathways that suppress MHC-I transcription. We argue the importance of applying a different therapeutic approach to paediatric tumours. In this context, inducing *de novo* MHC-I expression becomes crucial. Potential therapies for inducing MHC-I expression may involve activating pathways that directly or indirectly regulate MHC-I gene expression. In addition, inducing differentiation in paediatric tumours appears to be a promising strategy for improving immunotherapy outcomes and may also correlate with the upregulation of MHC-I expression. Overall, further investigation is urgently required to gain a deeper understanding of the underlying mechanisms involved in the regulation of MHC-I expression for individual patients and tumour types. Ideally, in analogy to the detection and quantification of acquired mutations at the individual cancer genome level using high-throughput methods, the screening of individual tumour material for MHC-I gene mutations or post-transcriptional changes in MHC-I genes should now be considered. Such an approach might help tailor the specificity of the treatment for a single patient and thereby improve therapeutic outcomes. As such, future research should explore novel strategies aimed at inducing MHC-I expression and identifying related pathway components to enhance the anti-tumour response, for application in immunotherapies.

Acknowledgements

We thank the members of Boes lab for helpful discussions. The Editor-in-Chief, Tim Elliott, and handling editor, Stephanie Dougan, would like to thank the two anonymous reviewers for their contribution to the publication of this article.

Author contributions

J.G., A.P., and M.B. wrote the manuscript.

Funding

Funding for this project was obtained from Lymph@Co (2018-LyCo-002), a Dutch non-profit research foundation that supports lymphoma research.

Conflict of interest

Marianne Boes is a Deputy Editor of Immunotherapy Advances and as such has been blinded from reviewing or making decisions on the manuscript. Other authors declare no other competing interests.

References

1. Ferlay J, Colombet M, Soerjomataram I *et al.* Cancer statistics for the year 2020: an overview. *Int J Cancer* 2021; 149(4):778–89.
2. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. *Int Immunopharmacol* 2018; 62(5):29–39. <https://doi.org/10.1016/j.intimp.2018.06.001>
3. Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. *AAPS J* 2021; 23(2):39. <https://doi.org/10.1208/s12248-021-00574-0>
4. Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. *J Med Toxicol* 2021; 17(4):411–24. <https://doi.org/10.1007/s13181-021-00833-8>

5. Esfahani K, Roudaia L, Buhlaiga N et al. A review of cancer immunotherapy: from the past, to the present, to the future. *Curr Oncol* 2020; 27(Suppl 2):S87–97. <https://doi.org/10.3747/co.27.5223>
6. Cable J, Greenbaum B, Pe'er D et al. Frontiers in cancer immunotherapy—a symposium report. *Ann N Y Acad Sci* 2021; 1489(1):30–47. <https://doi.org/10.1111/nyas.14526>
7. Galluzzi L, Chan TA, Kroemer G et al. The hallmarks of successful anticancer immunotherapy. *Sci Transl Med* 2018; 10(459):eaat7807. <https://doi.org/10.1126/scitranslmed.aat7807>
8. Wienke J, Dierselhuys MP, Tytgat GAM et al. The immune landscape of neuroblastoma: challenges and opportunities for novel therapeutic strategies in pediatric oncology. *Eur J Cancer* 2021; 144:123–50. <https://doi.org/10.1016/j.ejca.2020.11.014>
9. Jardim DL, Goodman A, de Melo Gagliato D et al. The challenges of tumor mutational burden as an immunotherapy biomarker. *Cancer Cell* 2021; 39(2):154–73. <https://doi.org/10.1016/j.ccell.2020.10.001>
10. Sha D, Jin Z, Budczies J et al. Tumor mutational burden as a predictive biomarker in solid tumors. *Cancer Discov* 2020; 10(12):1808–25. <https://doi.org/10.1158/2159-8290.CD-20-0522>
11. Jongsma MLM, Neefjes J, Spaapen RM. Playing hide and seek: tumor cells in control of MHC class I antigen presentation. *Mol Immunol* 2021; 136:36–44. <https://doi.org/10.1016/j.molimm.2021.05.009>
12. Cornel AM, Mimpfen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. *Cancers (Basel)* 2020; 12(7):1760. <https://doi.org/10.3390/cancers12071760>
13. Kallings A, Olszewski M, Maciejewska N et al. Cancer immune escape: the role of antigen presentation machinery. *J Cancer Res Clin Oncol* 2023; 149(10):8131–41. <https://doi.org/10.1007/s00432-023-04737-8>
14. Kattner P, Strobel H, Khoshnevis N et al. Compare and contrast: pediatric cancer versus adult malignancies. *Cancer Metastasis Rev* 2019; 38(4):673–82. <https://doi.org/10.1007/s10555-019-09836-y>
15. Spel L, Schiepers A, Boes M. NFkappaB and MHC-1 interplay in neuroblastoma and immunotherapy. *Trends Cancer* 2018; 4(11):715–7. <https://doi.org/10.1016/j.trecan.2018.09.006>
16. Bao R, Spranger S, Hernandez K et al. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. *J Immunother Cancer* 2021; 9(7):e002417.
17. Wang S, Xie K, Liu T. Cancer immunotherapies: from efficacy to resistance mechanisms - not only checkpoint matters. *Front Immunol* 2021; 12:690112. <https://doi.org/10.3389/fimmu.2021.690112>
18. Buferne M, Chasson L, Grange M et al. IFNgamma producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. *Oncoimmunology* 2015; 4(2):e974959. <https://doi.org/10.4161/2162402X.2014.974959>
19. Li H, Chiappinelli KB, Guzzetta AA et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. *Oncotarget* 2014; 5(3):587–98. <https://doi.org/10.18632/oncotarget.1782>
20. Boegel S, Lower M, Schafer M et al. HLA typing from RNA-Seq sequence reads. *Genome Med* 2012; 4(12):102. <https://doi.org/10.1186/gm403>
21. Boegel S, Lower M, Bukur T et al. HLA and proteasome expression body map. *BMC Med Genomics* 2018; 11(1):36. <https://doi.org/10.1186/s12920-018-0354-x>
22. Fiszer D, Kurpisz M. Major histocompatibility complex expression on human, male germ cells: a review. *Am J Reprod Immunol* 1998; 40(3):172–6. <https://doi.org/10.1111/j.1600-0897.1998.tb00409.x>
23. Rene C, Lozano C, Eliaou JF. Expression of classical HLA class I molecules: regulation and clinical impacts: Julia Bodmer Award Review 2015. *HLA* 2016; 87(5):338–49. <https://doi.org/10.1111/tan.12787>
24. Drukker M, Katz G, Urbach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. *Proc Natl Acad Sci U S A* 2002; 99(15):9864–9. <https://doi.org/10.1073/pnas.142298299>
25. Neefjes J, Jongsma ML, Paul P et al. Towards a systems understanding of MHC class I and MHC class II antigen presentation. *Nat Rev Immunol* 2011; 11(12):823–36. <https://doi.org/10.1038/nri3084>
26. Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. *Nat Rev Immunol* 2022; 22(12):751–64. <https://doi.org/10.1038/s41577-022-00707-2>
27. Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. *Cancers (Basel)* 2021; 13(1):134. <https://doi.org/10.3390/cancers13010134>
28. Rossjohn J, Gras S, Miles JJ et al. T cell antigen receptor recognition of antigen-presenting molecules. *Annu Rev Immunol* 2015; 33:169–200. <https://doi.org/10.1146/annurev-immunol-032414-112334>
29. Basu R, Whitlock BM, Husson J et al. Cytotoxic T cells use mechanical force to potentiate target cell killing. *Cell* 2016; 165(1):100–10. <https://doi.org/10.1016/j.cell.2016.01.021>
30. Fu Q, Fu TM, Cruz AC et al. Structural basis and functional role of intramembrane trimerization of the Fas/CD95 death receptor. *Mol Cell* 2016; 61(4):602–13. <https://doi.org/10.1016/j.molcel.2016.01.009>
31. Anfossi N, Andre P, Guia S et al. Human NK cell education by inhibitory receptors for MHC class I. *Immunity* 2006; 25(2):331–42. <https://doi.org/10.1016/j.immuni.2006.06.013>
32. Karre K, Ljunggren HG, Piontek G et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature* 1986; 319(6055):675–8. <https://doi.org/10.1038/319675a0>
33. Blander JM. Different routes of MHC-I delivery to phagosomes and their consequences to CD8 T cell immunity. *Semin Immunol* 2023; 66:101713. <https://doi.org/10.1016/j.smim.2023.101713>
34. Paul S, Lal G. The Molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. *Front Immunol* 2017; 8:1124. <https://doi.org/10.3389/fimmu.2017.01124>
35. Raskov H, Orhan A, Christensen JP et al. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. *Br J Cancer* 2021; 124(2):359–67. <https://doi.org/10.1038/s41416-020-01048-4>
36. Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. *Front Immunol* 2021; 12:636568. <https://doi.org/10.3389/fimmu.2021.636568>
37. Dusenbery AC, Maniaci JL, Hillerson ND et al. MHC class I loss in triple-negative breast cancer: a potential barrier to PD-1/PD-L1 checkpoint inhibitors. *Am J Surg Pathol* 2021; 45(5):701–7. <https://doi.org/10.1097/PAS.0000000000001653>
38. Lim SY, Shklovskaya E, Lee JH et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. *Nat Commun* 2023; 14(1):1516. <https://doi.org/10.1038/s41467-023-36979-y>
39. Montesin M, Murugesan K, Jin DX et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. *Cancer Discov* 2021; 11(2):282–92. <https://doi.org/10.1158/2159-8290.CD-20-0672>
40. Yoo SH, Keam B, Ock CY et al. Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. *Sci Rep* 2019; 9(1):7680. <https://doi.org/10.1038/s41598-019-44206-2>
41. White MC, Holman DM, Boehm JE et al. Age and cancer risk: a potentially modifiable relationship. *Am J Prev Med* 2014; 46(3 Suppl 1):S7–15. <https://doi.org/10.1016/j.amepre.2013.10.029>
42. Kippen R, James E, Ward B et al. Identification of cancer risk and associated behaviour: implications for social marketing campaigns for cancer prevention. *BMC Cancer* 2017; 17(1):550. <https://doi.org/10.1186/s12885-017-3540-x>

43. Parsa N. Environmental factors inducing human cancers. *Iran J Public Health* 2012; 41(11):1–9. <https://doi.org/10.1186/1479-5876-4-14>
44. Filbin M, Monje M. Developmental origins and emerging therapeutic opportunities for childhood cancer. *Nat Med* 2019; 25(3):367–76. <https://doi.org/10.1038/s41591-019-0383-9>
45. Funato K, Major T, Lewis PW et al. Use of human embryonic stem cells to model pediatric gliomas with H3K27M histone mutation. *Science* 2014; 346(6216):1529–33. <https://doi.org/10.1126/science.1253799>
46. Li Z, Godinho FJ, Klusmann JH et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. *Nat Genet* 2005; 37(6):613–9. <https://doi.org/10.1038/ng1566>
47. Lee JH, Shklovskaya E, Lim SY et al. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. *Nat Commun* 2020; 11(1):1897. <https://doi.org/10.1038/s41467-020-15726-7>
48. Shklovskaya E, Lee JH, Lim SY et al. Tumor MHC expression guides first-line immunotherapy selection in melanoma. *Cancers (Basel)* 2020; 12(11):3374. <https://doi.org/10.3390/cancers12113374>
49. Hurkmans DP, Kuipers ME, Smit J et al. Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients. *Cancer Immunol Immunother* 2020; 69(5):771–7. <https://doi.org/10.1007/s00262-020-02506-x>
50. Ichinokawa K, Nakanishi Y, Hida Y et al. Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in non-small-cell lung cancer. *Oncol Lett* 2019; 18(1):117–26. <https://doi.org/10.3892/ol.2019.10293>
51. Zhang B, Li J, Hua Q et al. Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation. *J Immunother Cancer* 2023; 11(1):e005592.
52. Geng N, Hu T, He C. Identification of DDX60 as a regulator of MHC-I class molecules in colorectal cancer. *Biomedicines* 2022; 10(12):3092.
53. Moretti M, La Rocca R, Perrone Donnorso M et al. Clustering of major histocompatibility complex-class I molecules in healthy and cancer colon cells revealed from their nanomechanical properties. *ACS Nano* 2021; 15(4):7500–12. <https://doi.org/10.1021/acsnano.1c00897>
54. Fang Y, Wang L, Wan C et al. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. *J Clin Invest* 2021; 131(1):e140837.
55. Zhao MZ, Sun Y, Jiang XF et al. Promotion on NLRC5 upregulating MHC-I expression by IFN-gamma in MHC-I-deficient breast cancer cells. *Immunol Res* 2019; 67(6):497–504. <https://doi.org/10.1007/s12026-019-09111-w>
56. Kowarschik S, Devi S, Grundemann C et al. Characterisation of *Viscum album* L. effect on immune escape proteins PD-L1, PD-L2 and MHC-I in prostate, colon, lung and breast cancer cells. *Complement Med Res* 2023; 30(5):386–92.
57. Korentzelos D, Wells A, Clark AM. Interferon-gamma increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer. *Sci Rep* 2022; 12(1):6657. <https://doi.org/10.1038/s41598-022-10724-9>
58. Garrido F, Ruiz-Cabello F, Aptsiauri N. Rejection versus escape: the tumor MHC dilemma. *Cancer Immunol Immunother* 2017; 66(2):259–71. <https://doi.org/10.1007/s00262-016-1947-x>
59. Cornel AM, Dunnebach E, Hofman DA et al. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. *J Immunother Cancer* 2022; 10(12):e005002. <https://doi.org/10.1136/jitc-2022-005002>
60. Lorenzi S, Forloni M, Cifaldi L et al. IRF1 and NF- κ B restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. *PLoS One* 2012; 7(10):e46928. <https://doi.org/10.1371/journal.pone.0046928>
61. Pistoia V, Morandi F, Bianchi G et al. Immunosuppressive microenvironment in neuroblastoma. *Front Oncol* 2013; 3:167. <https://doi.org/10.3389/fonc.2013.00167>
62. Wolff M, Jungbluth AA, Garrido F et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. *Cancer Immunol Immunother* 2005; 54(4):400–6. <https://doi.org/10.1007/s00262-004-0603-z>
63. Garancher A, Suzuki H, Haricharan S et al. Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. *Nat Neurosci* 2020; 23(7):842–53. <https://doi.org/10.1038/s41593-020-0628-4>
64. Smith C, Santi M, Rushing EJ et al. Characterization of signaling function and expression of HLA class I molecules in medulloblastoma. *J Neurooncol* 2011; 103(2):197–206. <https://doi.org/10.1007/s11060-010-0378-3>
65. Smith C, Santi M, Rajan B et al. A novel role of HLA class I in the pathology of medulloblastoma. *J Transl Med* 2009; 7:59. <https://doi.org/10.1186/1479-5876-7-59>
66. Biele E, Schober SJ, Prexler C et al. Monocyte maturation mediators upregulate CD83, ICAM-1 and MHC class 1 expression on ewing's sarcoma, enhancing T cell cytotoxicity. *Cells* 2021; 10(11):3070. <https://doi.org/10.3390/cells10113070>
67. Peters HL, Yan Y, Solheim JC. APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells. *Oncoimmunology* 2013; 2(10):e26293. <https://doi.org/10.4161/onci.26293>
68. Thiel U, Wolf P, Wawer A et al. Human leukocyte antigen distribution in German Caucasians with advanced Ewing's sarcoma. *Klin Padiatr* 2012; 224(6):353–8. <https://doi.org/10.1055/s-0032-1321730>
69. Chen X, MacNabb BW, Flood B et al. Divergent fates of antigen-specific CD8(+) T cell clones in mice with acute leukemia. *Cell Rep* 2021; 37(6):109991. <https://doi.org/10.1016/j.celrep.2021.109991>
70. Depreter B, De Moerloose B, Vandepoel K et al. Deciphering molecular heterogeneity in pediatric AML using a cancer vs normal transcriptomic approach. *Pediatr Res* 2021; 89(7):1695–705. <https://doi.org/10.1038/s41390-020-01199-3>
71. Kang SH, Hwang HJ, Yoo JW et al. Expression of immune checkpoint receptors on T-cells and their ligands on leukemia blasts in childhood acute leukemia. *Anticancer Res* 2019; 39(10):5531–9. <https://doi.org/10.21873/anticancer.13746>
72. Liu W, Hu H, Shao Z et al. Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma. *Bone Res* 2023; 11(1):4.
73. Tian H, Cao J, Li B et al. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. *Bone Res* 2023; 11(1):11. <https://doi.org/10.1038/s41413-023-00246-z>
74. Delgado D, Webster DE, DeSantes KB et al. KIR receptor-ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells. *Pediatr Blood Cancer* 2010; 55(7):1300–5. <https://doi.org/10.1002/pbc.22665>
75. Garrido F, Aptsiauri N, Doorduijn EM et al. The urgent need to recover MHC class I in cancers for effective immunotherapy. *Curr Opin Immunol* 2016; 39:44–51. <https://doi.org/10.1016/j.coi.2015.12.007>
76. Garrido F, Aptsiauri N. Cancer immune escape: MHC expression in primary tumours versus metastases. *Immunology* 2019; 158(4):255–66. <https://doi.org/10.1111/imm.13114>
77. Wiczorek M, Abualrous ET, Sticht J et al. Major histocompatibility complex (MHC) Class I and MHC class II proteins: conformational plasticity in antigen presentation. *Front Immunol* 2017; 8:292. <https://doi.org/10.3389/fimmu.2017.00292>
78. Agrawal S, Reemtsma K, Bagiella E et al. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. *Cell Immunol* 2004; 228(2):130–7. <https://doi.org/10.1016/j.cellimm.2004.04.006>
79. Benitez R, Godelaine D, Lopez-Nevot MA et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with

- MAGE peptides. *Tissue Antigens* 1998; 52(6):520–9. <https://doi.org/10.1111/j.1399-0039.1998.tb03082.x>
80. Lv L, Wei Q, Wang Z et al. Clinical and molecular correlates of NLRC5 expression in patients with melanoma. *Front Bioeng Biotechnol* 2021; 9:690186. <https://doi.org/10.3389/fbioe.2021.690186>
 81. Lazaridou MF, Massa C, Handke D et al. Identification of microRNAs targeting the transporter associated with antigen processing TAP1 in melanoma. *J Clin Med* 2020; 9(9):2690.
 82. Edidin M. Class I MHC molecules as probes of membrane patchiness: from biophysical measurements to modulation of immune responses. *Immunol Res* 2010; 47(1-3):265–72. <https://doi.org/10.1007/s12026-009-8159-9>
 83. Jongsma MLM, de Waard AA, Raaben M et al. The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses. *Immunity* 2021; 54(1):132–150.e9. <https://doi.org/10.1016/j.immuni.2020.11.003>
 84. Furukawa J, Tsuda M, Okada K et al. Comprehensive glycomics of a multistep human brain tumor model reveals specific glycosylation patterns related to malignancy. *PLoS One* 2015; 10(7):e0128300. <https://doi.org/10.1371/journal.pone.0128300>
 85. Wang Z, Wen L, Ma X et al. High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients. *Glycobiology* 2012; 22(7):930–8. <https://doi.org/10.1093/glycob/cws061>
 86. Wikstrand CJ, He XM, Fuller GN et al. Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo. *J Neuropathol Exp Neurol* 1991; 50(6):756–69. <https://doi.org/10.1097/00005072-199111000-00007>
 87. De Angelis Rigotti F, De Gassart A, Pffor C et al. MARCH9-mediated ubiquitination regulates MHC I export from the TGN. *Immunol Cell Biol* 2017; 95(9):753–64. <https://doi.org/10.1038/icb.2017.44>
 88. Reinicke AT, Raczkowski F, Muhlig M et al. Deubiquitinating enzyme UCH-L1 promotes dendritic cell antigen cross-presentation by favoring recycling of MHC class I molecules. *J Immunol* 2019; 203(7):1730–42. <https://doi.org/10.4049/jimmunol.1801133>
 89. Liu B, Palmfeldt J, Lin L et al. STAT3 associates with vacuolar H(+)-ATPase and regulates cytosolic and lysosomal pH. *Cell Res* 2018; 28(10):996–1012. <https://doi.org/10.1038/s41422-018-0080-0>
 90. Kang K, Xie F, Mao J et al. Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma. *Front Oncol* 2020; 10:573141. <https://doi.org/10.3389/fonc.2020.573141>
 91. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med* 2014; 371(23):2189–99. <https://doi.org/10.1056/NEJMoa1406498>
 92. Beauchemin L, Slifker M, Rossell D et al. Characterizing MHC-I genotype predictive power for oncogenic mutation probability in cancer patients. *Methods Mol Biol* 2020; 2131:185–98. https://doi.org/10.1007/978-1-0716-0389-5_8
 93. Grobner SN, Worst BC, Weischenfeldt J et al; ICGC PedBrainSeq Project. The landscape of genomic alterations across childhood cancers. *Nature* 2018; 555(7696):321–7. <https://doi.org/10.1038/nature25480>
 94. Kandath C, McLellan MD, Vandin F et al. Mutational landscape and significance across 12 major cancer types. *Nature* 2013; 502(7471):333–9. <https://doi.org/10.1038/nature12634>
 95. Frankiw L, Baltimore D, Li G. Alternative mRNA splicing in cancer immunotherapy. *Nat Rev Immunol* 2019; 19(11):675–87. <https://doi.org/10.1038/s41577-019-0195-7>
 96. Pont MJ, Oostvogels R, van Bergen CAM et al. T cells specific for an unconventional natural antigen fail to recognize leukemic cells. *Cancer Immunol Res* 2019; 7(5):797–804. <https://doi.org/10.1158/2326-6066.CIR-18-0137>
 97. Tran E, Robbins PF, Lu YC et al. T-cell transfer therapy targeting mutant KRAS in cancer. *N Engl J Med* 2016; 375(23):2255–62. <https://doi.org/10.1056/NEJMoa1609279>
 98. McGranahan N, Rosenthal R, Hiley CT et al; TRACERx Consortium. Allele-specific HLA loss and immune escape in lung cancer evolution. *Cell* 2017; 171(6):1259–1271.e11. <https://doi.org/10.1016/j.cell.2017.10.001>
 99. Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. *Cancer Cell* 2020; 37(4):443–55. <https://doi.org/10.1016/j.ccell.2020.03.017>
 100. Carretero R, Romero JM, Ruiz-Cabello F et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. *Immunogenetics* 2008; 60(8):439–47. <https://doi.org/10.1007/s00251-008-0303-5>
 101. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015; 348(6230):124–8. <https://doi.org/10.1126/science.aaa1348>
 102. Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science* 2015; 350(6257):207–11. <https://doi.org/10.1126/science.aad0095>
 103. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. *N Engl J Med* 2017; 377(25):2500–1. <https://doi.org/10.1056/NEJMc1713444>
 104. Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N Engl J Med* 2016; 375(9):819–29. <https://doi.org/10.1056/NEJMoa1604958>
 105. Romero I, Garrido C, Algarra I et al. T lymphocytes restrain spontaneous metastases in permanent dormancy. *Cancer Res* 2014; 74(7):1958–68. <https://doi.org/10.1158/0008-5472.CAN-13-2084>
 106. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 2014; 515(7528):568–71. <https://doi.org/10.1038/nature13954>
 107. Ren H, Cao K, Wang M. A correlation between differentiation phenotypes of infused T cells and anti-cancer immunotherapy. *Front Immunol* 2021; 12:745109. <https://doi.org/10.3389/fimmu.2021.745109>
 108. Wedekind MF, Denton NL, Chen CY et al. Pediatric cancer immunotherapy: opportunities and challenges. *Paediatr Drugs* 2018; 20(5):395–408. <https://doi.org/10.1007/s40272-018-0297-x>
 109. Hingorani P, Maas ML, Gustafson MP et al. Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients. *J ImmunoTher Cancer* 2015; 3:35. <https://doi.org/10.1186/s40425-015-0082-0>
 110. Merchant MS, Wright M, Baird K et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. *Clin Cancer Res* 2016; 22(6):1364–70. <https://doi.org/10.1158/1078-0432.CCR-15-0491>
 111. Tawbi HA, Burgess M, Bolejack V et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol* 2017; 18(11):1493–501. [https://doi.org/10.1016/S1470-2045\(17\)30624-1](https://doi.org/10.1016/S1470-2045(17)30624-1)
 112. Georger B, Kang HJ, Yalon-Oren M et al. Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1(+) advanced, relapsed, or refractory solid tumor or lymphoma. *J Clin Oncol* 2017; 35(15):10525–10525.
 113. Greve P, Meyer-Wentrup FAG, Peperzak V et al. Upcoming immunotherapeutic combinations for B-cell lymphoma. *Immunother Adv* 2021; 1(1):ltab001. <https://doi.org/10.1093/immadv/ltab001>
 114. Lanier LL. NK cell receptors. *Annu Rev Immunol* 1998; 16:359–93. <https://doi.org/10.1146/annurev.immunol.16.1>
 115. Groth A, Kloss S, von Strandmann EP et al. Mechanisms of tumor and viral immune escape from natural killer cell-mediated

- surveillance. *J Inmate Immun* 2011; 3(4):344–54. <https://doi.org/10.1159/000327014>
116. Mamessier E, Sylvain A, Thibault ML et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. *J Clin Invest* 2011; 121(9):3609–22. <https://doi.org/10.1172/JCI45816>
 117. Vitale M, Cantoni C, Pietra G et al. Effect of tumor cells and tumor microenvironment on NK-cell function. *Eur J Immunol* 2014; 44(6):1582–92. <https://doi.org/10.1002/eji.201344272>
 118. Cozar B, Greppi M, Carpentier S et al. Tumor-infiltrating natural killer cells. *Cancer Discov* 2021; 11(1):34–44. <https://doi.org/10.1158/2159-8290.CD-20-0655>
 119. Jonges LE, Giezeman-Smits KM, van Vlierbergh RL et al. NK cells modulate MHC class I expression on tumor cells and their susceptibility to lysis. *Immunobiology* 2000; 202(4):326–38. [https://doi.org/10.1016/s0171-2985\(00\)80037-6](https://doi.org/10.1016/s0171-2985(00)80037-6)
 120. Spel L, Boelens JJ, van der Steen DM et al. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. *Oncotarget* 2015; 6(34):35770–81. <https://doi.org/10.18632/oncotarget.5657>
 121. Watson NF, Ramage JM, Madjd Z et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. *Int J Cancer* 2006; 118(1):6–10. <https://doi.org/10.1002/ijc.21303>
 122. de Vries NL, van de Haar J, Veninga V et al. gammadelta T cells are effectors of immunotherapy in cancers with HLA class I defects. *Nature* 2023; 613(7945):743–50. <https://doi.org/10.1038/s41586-022-05593-1>
 123. Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. *Front Immunol* 2022; 13:844866. <https://doi.org/10.3389/fimmu.2022.844866>
 124. Zhou F. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. *Int Rev Immunol* 2009; 28(3-4):239–60. <https://doi.org/10.1080/08830180902978120>
 125. Grenga I, Donahue RN, Lepone L, Bame J et al. PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment. *J ImmunoTher Cancer* 2014; 2(Suppl 3):102–102.
 126. Rodriguez T, Mendez R, Del Campo A et al. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. *BMC Cancer* 2007;34(7). <https://doi.org/10.1186/1471-2407-7-34>
 127. Miller CH, Maher SG, Young HA. Clinical use of interferon-gamma. *Ann N Y Acad Sci* 2009; 1182(1):69–79. <https://doi.org/10.1111/j.1749-6632.2009.05069.x>
 128. Khorana AA, Rosenblatt JD, Sahasrabudhe DM et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. *Cancer Gene Ther* 2003; 10(4):251–9. <https://doi.org/10.1038/sj.cgt.7700568>
 129. Chew GL, Campbell AE, De Neef E et al. DUX4 suppresses MHC class I to promote cancer immune evasion and resistance to checkpoint blockade. *Dev Cell* 2019; 50(5):658–671.e7. <https://doi.org/10.1016/j.devcel.2019.06.011>
 130. Ding LW, Sun QY, Edwards JJ et al. LNK suppresses interferon signaling in melanoma. *Nat Commun* 2019; 10(1):2230.
 131. Zheng H, Alter S, Qu CK. SHP-2 tyrosine phosphatase in human diseases. *Int J Clin Exp Med* 2009; 2(1):17–25.
 132. Xia L, Tan S, Zhou Y et al. Role of the NFkappaB-signaling pathway in cancer. *Onco Targets Ther* 2018; 11(11):2063–73. <https://doi.org/10.2147/OTT.S161109>
 133. Zinatizadeh MR, Schock B, Chalbatani GM et al. The nuclear factor kappa B (NF-kB) signaling in cancer development and immune diseases. *Genes Dis* 2021; 8(3):287–97. <https://doi.org/10.1016/j.gendis.2020.06.005>
 134. Spel L, Nieuwenhuis J, Haarsma R et al. Nedd4-binding protein 1 and TNFAIP3-interacting protein 1 control MHC-1 display in neuroblastoma. *Cancer Res* 2018; 78(23):6621–31. <https://doi.org/10.1158/0008-5472.CAN-18-0545>
 135. Meissner TB, Li A, Biswas A et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. *Proc Natl Acad Sci U S A* 2010; 107(31):13794–9. <https://doi.org/10.1073/pnas.1008684107>
 136. Neerinx A, Rodriguez GM, Steimle V et al. NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner. *J Immunol* 2012; 188(10):4940–50. <https://doi.org/10.4049/jimmunol.1103136>
 137. Yoshihama S, Roszik J, Downs I et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. *Proc Natl Acad Sci U S A* 2016; 113(21):5999–6004. <https://doi.org/10.1073/pnas.1602069113>
 138. Yoshihama S, Vijayan S, Sidiq T et al. NLRC5/CITA: a key player in cancer immune surveillance. *Trends Cancer* 2017; 3(1):28–38. <https://doi.org/10.1016/j.trecan.2016.12.003>
 139. Luo N, Nixon MJ, Gonzalez-Ericsson PI et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. *Nat Commun* 2018; 9(1):248. <https://doi.org/10.1038/s41467-017-02630-w>
 140. Fonsatti E, Sigalotti L, Coral S et al. Methylation-regulated expression of HLA class I antigens in melanoma. *Int J Cancer* 2003; 105(3):430–1; author reply 432. <https://doi.org/10.1002/ijc.11077>
 141. Woods DM, Sodre AL, Villagra A et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. *Cancer Immunol Res* 2015; 3(12):1375–85. <https://doi.org/10.1158/2326-6066.CIR-15-0077-T>
 142. Wrangle J, Wang W, Koch A et al. Alterations of immune response of non-small cell lung cancer with azacytidine. *Oncotarget* 2013; 4(11):2067–79. <https://doi.org/10.18632/oncotarget.1542>
 143. Franklin DA, James JL, Axelrod ML et al. MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression. *Cancer Drug Resist* 2020; 3(3):603–12. <https://doi.org/10.20517/cdr.2019.109>
 144. Lulli D, Carbone ML, Pastore S. The MEK inhibitors trametinib and cobimetinib induce a type I interferon response in human keratinocytes. *Int J Mol Sci* 2017; 18(10):2227. <https://doi.org/10.3390/ijms18102227>
 145. Watanabe S, Hayashi H, Haratani K et al. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer. *Cancer Sci* 2019; 110(1):52–60. <https://doi.org/10.1111/cas.13860>
 146. Pulido M, Chamorro V, Romero I et al. Restoration of MHC-I on tumor cells by fhit transfection promotes immune rejection and acts as an individualized immunotherapeutic vaccine. *Cancers (Basel)* 2020; 12(6):1563.
 147. del Campo AB, Aptsiauri N, Mendez R et al. Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. *Scand J Immunol* 2009; 70(2):125–35. <https://doi.org/10.1111/j.1365-3083.2009.02276.x>
 148. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012; 2(5):401–4. <https://doi.org/10.1158/2159-8290.CD-12-0095>
 149. Marijt KA, Blijleven L, Verdegaal EME et al. Identification of non-mutated neoantigens presented by TAP-deficient tumors. *J Exp Med* 2018; 215(9):2325–37. <https://doi.org/10.1084/jem.20180577>
 150. Artzt K, Jacob FL. Absence of serologically detectable H-2 on primitive teratocarcinoma cells in culture. *Transplantation* 1974; 17(6):632–4.
 151. Andrews PW. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro.

- Dev Biol* 1984; 103(2):285–93. [https://doi.org/10.1016/0012-1606\(84\)90316-6](https://doi.org/10.1016/0012-1606(84)90316-6)
152. Hedley ML, Drake BL, Head JR et al. Differential expression of the class I MHC genes in the embryo and placenta during midgestational development in the mouse. *J Immunol* 1989; 142(11):4046–53.
153. Matthay KK, Reynolds CP, Seeger RC et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. *J Clin Oncol* 2009; 27(7):1007–13. <https://doi.org/10.1200/JCO.2007.13.8925>
154. Ortega JJ, Madero L, Martin G et al; PETHEMA Group. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. *J Clin Oncol* 2005; 23(30):7632–40. <https://doi.org/10.1200/JCO.2005.01.3359>
155. Teppola H, Sarkanen JR, Jalonen TO et al. Morphological differentiation towards neuronal phenotype of SH-SY5Y neuroblastoma cells by estradiol, retinoic acid and cholesterol. *Neurochem Res* 2016; 41(4):731–47. <https://doi.org/10.1007/s11064-015-1743-6>
156. Farina AR, Masciulli MP, Tacconelli A et al. All-trans-retinoic acid induces nuclear factor kappaB activation and matrix metalloproteinase-9 expression and enhances basement membrane invasivity of differentiation-resistant human SK-N-BE 9N neuroblastoma Cells. *Cell Growth Differ* 2002; 13(8):343–54.